The tumour microenvironment and implications for cancer immunotherapy
- 29 June 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 6 (7) , 671-684
- https://doi.org/10.1517/14712598.6.7.671
Abstract
Tumour cells exist in a complex milieu of cellular and non-cellular components comprising fibroblasts, endothelial cells, immune cells and metabolites of cellular respiration. An elaborate interplay between these components and tumour cells exists with implications for immunological recognition of tumour cells. Tumours have been shown to alter their antigen and cytokine profiles, desensitise and impair immune defences, signal fibroblasts to facilitate metastasis, and take advantage of acidic and hypoxic conditions that impede normal cells. This paper aims to review the roles of the stroma, extracellular matrix and chemistry of the microenvironment on tumour growth, with particular emphasis on interactions with the immune system, and to highlight some of the novel therapeutic strategies that target the tumour microenvironment.Keywords
This publication has 94 references indexed in Scilit:
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJournal of Clinical Investigation, 2005
- Manipulating the Local Tumor Microenvironment with Poxviruses Expressing Costimulatory MoleculesAnnals of the New York Academy of Sciences, 2005
- Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and DocetaxelClinical Cancer Research, 2005
- Indoleamine 2,3 dioxygenase and regulation of T cell immunityBiochemical and Biophysical Research Communications, 2005
- Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunityJournal of Leukocyte Biology, 2005
- Stromal fibroblasts in cancer initiation and progressionNature, 2004
- Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)Journal of Biological Chemistry, 2004
- Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumorsTissue Antigens, 2003
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Lack of interleukin‐2 (IL‐2) expression and selective expression of IL‐10 mRNA in human renal cell carcinomaInternational Journal of Cancer, 1995